FDA's Lillian Yin
This article was originally published in The Gray Sheet
Director of the division of reproductive, abdominal, ear nose & throat and radiological devices in FDA's Office of Device Evaluation moves to the Center for Biologics Evaluation and Research in order to work on CBER's action plan for the regulation of devices ("The Gray Sheet" Dec. 7, p. 22). DRAERD Chief Medical Officer Dan Schultz is replacing Yin on an acting basis. Also leaving CDRH to join CBER is Mary Beth Jacobs, director of the division of life sciences within the Office of Science and Technology
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.